Dear Doctor - Participate in the Survey on thromboprophylaxis " A recent survey of patients with thrombophilia found that most patients are not receiving adequate thromboprophylaxis. Thrombophilia is a condition that predisposes patients to developing blood clots, and thromboprophylaxis is the use of medication or other interventions to prevent blood clots from forming.The survey found that only 43% of patients with thrombophilia were receiving anticoagulant medication, which is the most effective form of thromboprophylaxis. This means that the majority of patients with thrombophilia are not being adequately protected from developing blood clots.There are several reasons why patients with thrombophilia may not be receiving appropriate thromboprophylaxis. First, many patients are not aware that they have thrombophilia. Second, even when patients are aware of their condition, they may not be aware of the importance of using anticoagulants or other forms of thromboprophylaxis. Third, some patients may be reluctant to take anticoagulants because of the potential side effects. Finally, some physicians may not be familiar with the latest guidelines for managing thrombophilia and therefore may not be prescribing anticoagulants to their patients with this condition.The results of this survey underscore the need for better education for both patients and physicians about thrombophilia . Participate in Surveys "
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.
3.
Obesity linked to subsequent neoplasms in childhood cancer survivors
4.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
5.
In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.
1.
Colon Cancer Staging: What You Need to Know
2.
Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes
3.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
4.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
5.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
3.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
4.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
5.
Should We Use DARA Up Front As First-Line Therapy in MM?
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation